Cantor Fitzgerald Weighs in on InflaRx FY2026 Earnings

InflaRx (NASDAQ:IFRX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of InflaRx in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the company will post earnings of ($0.65) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $10.00 price objective on the stock. The consensus estimate for InflaRx's current full-year earnings is ($1.04) per share.

A number of other research analysts have also commented on IFRX. HC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of InflaRx in a research note on Friday, March 21st. Oppenheimer decreased their price target on InflaRx from $6.00 to $3.00 and set an "outperform" rating for the company in a research note on Thursday, May 29th. Guggenheim boosted their price objective on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, March 26th. Finally, Raymond James lowered InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 price objective for the company. in a report on Thursday, May 29th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $6.60.

InflaRx Stock Performance

Shares of IFRX stock traded down $0.01 during midday trading on Tuesday, reaching $0.84. 317,846 shares of the company were exchanged, compared to its average volume of 277,298. The company's 50 day moving average price is $1.29 and its two-hundred day moving average price is $1.78. The company has a market cap of $56.39 million, a P/E ratio of -0.78 and a beta of 1.29. InflaRx has a 12 month low of $0.71 and a 12 month high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%.

Institutional Trading of InflaRx

Large investors have recently added to or reduced their stakes in the business. Northern Trust Corp grew its holdings in shares of InflaRx by 1,933.1% in the 4th quarter. Northern Trust Corp now owns 666,845 shares of the company's stock worth $1,647,000 after acquiring an additional 634,045 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of InflaRx by 32.8% in the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after purchasing an additional 11,900 shares during the period. Raymond James Financial Inc. purchased a new position in InflaRx in the 4th quarter worth about $1,576,000. Cubist Systematic Strategies LLC acquired a new stake in InflaRx during the 4th quarter worth about $55,000. Finally, Commonwealth Equity Services LLC lifted its stake in InflaRx by 20.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock valued at $275,000 after buying an additional 19,000 shares in the last quarter. 42.39% of the stock is currently owned by institutional investors.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.